Thomas Thomas

Dr. Thomas Thomas


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
OYOussama Yahiaoui
Oussama Yahiaoui
LPLukáš Félix Pašteka
Lukáš Félix Pašteka
BJBernadette Judeel
Bernadette Judeel
TTThomas Thomas
Thomas Thomas

1 December 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
ABAndré P. Birvé
André P. Birvé
HPHarshal D. Patel
Harshal D. Patel
JPJason R. Price
Jason R. Price
WBWitold Bloch
Witold Bloch
TTThomas Thomas
Thomas Thomas
A fluxional bis‐monodentate ligand, based on the archetypal shape‐shifting molecule bullvalene, self‐assembles with M2+ (M=Pd2+ or Pt2+) to produce a highly complex ensemble of permanently fluxional coordination cages. Metal‐mediated self‐assembly selects for an M2L4 architecture while maintaining shape‐shifting ligand complexity. A second level of simplification is achieved with guest‐exchange; the binding of halides within the M2L4 cage mixture results in a convergence to a cage species with all four ligands present as the “B isomer”. Within this confine, the reaction graph of the bullvalene is greatly restricted, but gives rise to a mixture of 38 possible diastereoisomers in rapid exchange. X‐ray crystallography reveals a preference for an achiral form consisting of both ligand enantiomers. Through a combination of NMR spectroscopy and DFT calculations, we elucidate the restricted isomerisation pathway of the permanently fluxional M2L4 assembly.

10 February 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HPHarshal D. Patel
Harshal D. Patel
TTThanh-Huyen Tran
Thanh-Huyen Tran
CSChristopher Sumby
Christopher Sumby
LPLukáš Félix Pašteka
Lukáš Félix Pašteka
TTThomas Thomas
Thomas Thomas

24 September 2019 in Organic Letters
Verified
Journal Article
Closed access
LMLauren A. M. Murray
Lauren A. M. Murray
TTThomas Thomas
Thomas Thomas
CSChristopher Sumby
Christopher Sumby
JGJonathan H. George
Jonathan H. George

20 March 2015 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
TTThomas Thomas
Thomas Thomas
MOMartin Oestreich
Martin Oestreich

3 April 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AOAlessandra Ottonello
Alessandra Ottonello
JWJessica A. Wyllie
Jessica A. Wyllie
OYOussama Yahiaoui
Oussama Yahiaoui
SSShoujun Sun
Shoujun Sun
RKRebecca A. Koelln
Rebecca A. Koelln
JMJohn Edward Moses
John Edward Moses
The alarming rise in superbugs that are resistant to drugs of last resort, including vancomycin-resistant enterococci and staphylococci, has become a significant global health hazard. Here, we report the click chemistry synthesis of an unprecedented class of shapeshifting vancomycin dimers (SVDs) that display potent activity against bacteria that are resistant to the parent drug, including the ESKAPE pathogens, vancomycin-resistant Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), as well as vancomycin-resistant S. aureus (VRSA). The shapeshifting modality of the dimers is powered by a triazole-linked bullvalene core, exploiting the dynamic covalent rearrangements of the fluxional carbon cage and creating ligands with the capacity to inhibit bacterial cell wall biosynthesis. The new shapeshifting antibiotics are not disadvantaged by the common mechanism of vancomycin resistance resulting from the alteration of the C-terminal dipeptide with the corresponding d -Ala- d -Lac depsipeptide. Further, evidence suggests that the shapeshifting ligands destabilize the complex formed between the flippase MurJ and lipid II, implying the potential for a new mode of action for polyvalent glycopeptides. The SVDs show little propensity for acquired resistance by enterococci, suggesting that this new class of shapeshifting antibiotic will display durable antimicrobial activity not prone to rapidly acquired clinical resistance.